SynthesisFrontiers in neurology2026
Tranexamic acid for neurological outcomes and mortality in adults with hemorrhagic acute brain injury: an updated systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemorrhagic acute brain injury-encompassing traumatic brain injury, spontaneous intracerebral hemorrhage, and subarachnoid hemorrhage-carries substantial morbidity and mortality. Active hemorrhage and hematoma progression constitute shared pathological mechanisms across these conditions. As a lysine analog anti-fibrinolytic, tranexamic acid (TXA) has demonstrated mortality reduction in extracranial bleeding; however, its efficacy and safety in intracranial hemorrhagic lesions remain inconclusive. Prior systematic reviews predominantly targeted single disease categories, inadequately assessed core outcomes such as all-cause mortality and neurological functional recovery, and seldom applied the Risk of Bias 2 tool or GRADE framework for methodological appraisal. Therefore, an updated meta-analysis is warranted to re-evaluate the overall clinical value of TXA in hemorrhagic acute brain injury. Objective: To evaluate the effect of TXA on neurological outcomes and all-cause mortality in adults with acute brain injury. Methods: This meta-analysis was registered with PROSPERO (CRD420261400869). In accordance with the PRISMA 2020 statement, we systematically searched PubMed, EMBASE, Scopus, Web of Science, and the Cochrane Library from inception to April 2026. Eligible studies were randomized controlled trials comparing TXA with placebo in hospitalized adults with acute brain injury, including traumatic brain injury, spontaneous intracranial hemorrhage, and subarachnoid hemorrhage. Risk of bias was assessed using the RoB 2 tool, the certainty of evidence was evaluated using the GRADE framework, pooled effect estimates were generated using a random-effects model, heterogeneity was quantified using the Results: Seven high-quality randomized controlled trials comprising over 12,000 patients were included. Random-effects model analyses showed no statistically significant effect of TXA on short-term mortality (RR 0.93, 95% CI 0.86-1.00) or long-term mortality (RR 1.02, 95% CI 0.91-1.13). For neurological outcomes, TXA neither improved the proportion of patients with functional independence (RR 0.97, 95% CI 0.92-1.03) nor reduced the risk of functional dependence or death (RR 1.01, 95% CI 0.96-1.07). For rebleeding, the pooled estimate showed no statistically significant effect (RR 0.81, 95% CI 0.59-1.11), with substantial between-study heterogeneity ( Conclusion: TXA did not improve all-cause mortality or neurological outcomes in hemorrhagic acute brain injury, and the evidence for its effect on rebleeding remains inconclusive. Systematic review registration: PROSPERO, CRD420261400869.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.